Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Esophagogastric Cancer 1Breast Cancer Metastases 1

Interventions

Radiosurgery 58Radiotherapy 43Magnetic Resonance Spectroscopy 39Cyclophosphamide 34Standard of Care 30Surveys and Questionnaires 22Dexamethasone 19Educational Status 18Therapeutics 17Exercise 17Radiation 16Magnetic Resonance Imaging 16fludarabine phosphate 15Proton Therapy 15Practice Guidelines as Topic 15Methods 15Mammography 15Fluorodeoxyglucose F18 15Cisplatin 15Blood Specimen Collection 15Acupuncture Therapy 15Doxorubicin 14fludarabine 13Positron-Emission Tomography 13Calcium Dobesilate 13Biopsy 13Surgical Procedures, Operative 12Radiotherapy, Intensity-Modulated 12Palliative Care 12Indocyanine Green 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Has results × zirconium-89-trastuzumab × Clear all
NCT02023996 2024-12-10

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center

Phase NA Completed
42 enrolled 11 charts
Gastrointestinal

Esophagogastric Cancer

NCT02286843 2021-06-18

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Memorial Sloan Kettering Cancer Center

Phase NA Completed
49 enrolled 8 charts
Breast

Breast Cancer Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡